drugset
drugset / Trial / NCT06171880

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

NCT06171880 ↗

Phase 1 Completed 48 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JC-001 and JLP-1901

Timeline

Start
2022-02-15
Primary completion
2022-03-11
Completion
2022-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject JC-001 Unknown — —
Subject JLP-1901 Unknown — —

Indications

No indication recorded.